{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:35:36Z","timestamp":1771054536561,"version":"3.50.1"},"reference-count":89,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.canlet.2004.11.011","type":"journal-article","created":{"date-parts":[[2004,12,16]],"date-time":"2004-12-16T00:31:45Z","timestamp":1103157105000},"page":"203-212","source":"Crossref","is-referenced-by-count":49,"title":["Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer"],"prefix":"10.1016","volume":"224","author":[{"given":"Lev M.","family":"Berstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2004.11.011_bib1","first-page":"211","article-title":"Studies on the antitumoral activity of the biguanides. V. Effect on the respiration of tumor cells","volume":"10","author":"Lugaro","year":"1967","journal-title":"Arch. Ital. Patol. Clin. Tumori."},{"key":"10.1016\/j.canlet.2004.11.011_bib2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000224450","article-title":"Proposed treatment of cancer by inhibition of gluconeogenesis","volume":"22","author":"Gold","year":"1968","journal-title":"Oncology"},{"key":"10.1016\/j.canlet.2004.11.011_bib3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000225663","article-title":"Effects of misclerone (clofibrate) on dimethylhydrazine-induced intestinal carcinogenesis in rats","volume":"39","author":"Berstein","year":"1982","journal-title":"Oncology"},{"key":"10.1016\/j.canlet.2004.11.011_bib4","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1172\/JCI112165","article-title":"Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase","volume":"76","author":"Maltese","year":"1985","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2004.11.011_bib5","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/jnci\/96.10.732","article-title":"Metabolomics takes its place as latest up-and-coming \u2018omic\u2019 science","volume":"96","author":"Schmidt","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2004.11.011_bib6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1365-2796.2000.00625.x","article-title":"Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted?","volume":"247","author":"Zimmet","year":"2000","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.canlet.2004.11.011_bib7","series-title":"Four Models of Medicine","author":"Dilman","year":"1987"},{"key":"10.1016\/j.canlet.2004.11.011_bib8","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1210\/er.2002-0010","article-title":"Insulin resistance and chronic cardiovascular inflammatory syndrome","volume":"24","author":"Fernandez-Real","year":"2003","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.canlet.2004.11.011_bib9","series-title":"Development, Ageing and Disease. A New Rationale for an Intervention Strategy","author":"Dilman","year":"1994"},{"key":"10.1016\/j.canlet.2004.11.011_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000225596","article-title":"Metabolic immunodepression and metabolic immunotherapy: an attempt of improvement in immunologic response in breast cancer patients by correction of metabolic disturbances","volume":"39","author":"Dilman","year":"1982","journal-title":"Oncology"},{"key":"10.1016\/j.canlet.2004.11.011_bib11","series-title":"La Chemie du Cancer, Paris","author":"Roffo","year":"1933"},{"key":"10.1016\/j.canlet.2004.11.011_bib12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1146\/annurev.nu.12.070192.002135","article-title":"Serum cholesterol and cancer risk: an epidemiologic perspectives","volume":"12","author":"Kritchevsky","year":"1992","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.canlet.2004.11.011_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jama.275.1.55","article-title":"Carcinogenicity of lipid-lowering drugs","volume":"275","author":"Newman","year":"1996","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.canlet.2004.11.011_bib14","first-page":"631","article-title":"Cholesterolemia and total, cardiovascular and cancer mortality. Study of a cohort of 220,000 people","volume":"182","author":"Guize","year":"1998","journal-title":"Bull. Acad. Natl. Med."},{"key":"10.1016\/j.canlet.2004.11.011_bib15","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1001\/jama.290.22.2959","article-title":"Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals","volume":"290","author":"Lieberman","year":"2003","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.canlet.2004.11.011_bib16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jama.275.1.67","article-title":"Does lowering of cholesterol cause cancer?","volume":"275","author":"Dalen","year":"1996","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.canlet.2004.11.011_bib17","first-page":"251","article-title":"Membrane fluidity in malignancy. Adversative and recuperative","volume":"738","author":"Shinitzky","year":"1984","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2004.11.011_bib18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1615\/JEnvPathToxOncol.v22.i2.10","article-title":"Molecular regulation of cholesterol biosynthesis: implications in carcinogenesis","volume":"22","author":"Singh","year":"2003","journal-title":"J. Environ. Pathol. Toxicol. Oncol."},{"key":"10.1016\/j.canlet.2004.11.011_bib19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/jcb.10724","article-title":"Cholesterol and prostate cancer","volume":"91","author":"Freeman","year":"2004","journal-title":"J. Cell Biochem."},{"key":"10.1016\/j.canlet.2004.11.011_bib20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1152\/physrev.1995.75.3.473","article-title":"Pathophysiology of insulin resistance in human disease","volume":"75","author":"Reaven","year":"1995","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.canlet.2004.11.011_bib21","series-title":"The Law of Deviation of Homeostasis and Diseases of Aging","author":"Dilman","year":"1981"},{"key":"10.1016\/j.canlet.2004.11.011_bib22","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/aje\/kwg100","article-title":"Abnormal glucose tolerance and the risk of cancer death in the United States","volume":"157","author":"Saydah","year":"2003","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.canlet.2004.11.011_bib23","first-page":"121","article-title":"Cancer proneness profile. A study of ponderal index and blood glucose","volume":"24","author":"Cheraskin","year":"1969","journal-title":"Geriatrics"},{"key":"10.1016\/j.canlet.2004.11.011_bib24","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1126\/science.1082889","article-title":"Mitochondrial dysfunction in the elderly: possible role in insulin resistance","volume":"300","author":"Petersen","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.canlet.2004.11.011_bib25","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1210\/er.20.4.535","article-title":"The insulin-related ovarian regulatory system in health and disease","volume":"20","author":"Poretzky","year":"1999","journal-title":"Endocrinol. Rev."},{"key":"10.1016\/j.canlet.2004.11.011_bib26","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrc1387","article-title":"Insulin-like growth factors and neoplasia","volume":"4","author":"Pollak","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2004.11.011_bib27","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000074502","article-title":"Importance of adipocytokines in insulin resistance and obesity-related diseases","volume":"60","author":"Matsuzawa","year":"2003","journal-title":"Horm. Res."},{"key":"10.1016\/j.canlet.2004.11.011_bib28","doi-asserted-by":"crossref","first-page":"28668","DOI":"10.1074\/jbc.M301695200","article-title":"Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line","volume":"278","author":"Catalano","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2004.11.011_bib29","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1210\/jc.2003-031804","article-title":"Adiponectin and breast cancer risk","volume":"89","author":"Mantzoros","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2004.11.011_bib30","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1210\/jc.86.8.3574","article-title":"Insulin resistance as a predictor of age-related diseases","volume":"86","author":"Facchini","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2004.11.011_bib31","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/jnci\/djh082","article-title":"A prospective study of plasma C-peptide and colorectal cancer risk in men","volume":"96","author":"Ma","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2004.11.011_bib32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1200\/JCO.20.1.42","article-title":"Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study","volume":"20","author":"Goodwin","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2004.11.011_bib33","series-title":"Macrosomy, Obesity and Cancer","author":"Berstein","year":"1997"},{"key":"10.1016\/j.canlet.2004.11.011_bib34","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.20.4.1128","article-title":"Weight loss in breast cancer patient management","volume":"20","author":"Chlebowski","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2004.11.011_bib35","series-title":"American Society of Clinical Oncology (ASCO) Educational Book, 40th Annual Meeting","article-title":"Obesity and cancer: potential management strategies","author":"McTiernan","year":"2004"},{"key":"10.1016\/j.canlet.2004.11.011_bib36","series-title":"American Society of Clinical Oncology (ASCO) Educational Book, 40th Annual Meeting","article-title":"Obesity and cancer outcomes","author":"Goodwin","year":"2004"},{"key":"10.1016\/j.canlet.2004.11.011_bib37","first-page":"1055","article-title":"Potential antitumor effects of statins (Review)","volume":"23","author":"Jakobisiak","year":"2003","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2004.11.011_bib38","first-page":"10","article-title":"The statins as anticancer agents","volume":"9","author":"Chan","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2004.11.011_bib39","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0898-6568(02)00124-9","article-title":"Molecular mechanisms of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells","volume":"15","author":"Denoyelle","year":"2003","journal-title":"Cell Signal."},{"key":"10.1016\/j.canlet.2004.11.011_bib40","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1046\/j.1464-5491.2003.00993.x","article-title":"Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose","volume":"20","author":"Costa","year":"2003","journal-title":"Diabetes Med."},{"key":"10.1016\/j.canlet.2004.11.011_bib41","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.2165\/00003495-200363180-00001","article-title":"Metformin: new understandings, new uses","volume":"63","author":"Hundal","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.canlet.2004.11.011_bib42","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S1262-3636(03)72785-2","article-title":"Reducing insulin resistance with metformin: the evidence today","volume":"29","author":"Giannarelli","year":"2003","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.canlet.2004.11.011_bib43","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.lfs.2003.07.015","article-title":"Effects of phenformin on the proliferation of human tumor cell lines","volume":"74","author":"Caraci","year":"2003","journal-title":"Life Sci."},{"key":"10.1016\/j.canlet.2004.11.011_bib44","first-page":"1","article-title":"Inhibition of DMBA-induced carcinogenesis by phenformin in the mammary glands of rats","volume":"43","author":"Dilman","year":"1978","journal-title":"Archiv f. Geschwulstf."},{"key":"10.1016\/j.canlet.2004.11.011_bib45","first-page":"303","article-title":"Insulin and longevity: antidiabetic biguanides as geroprotectors","volume":"4","author":"Anisimov","year":"2003","journal-title":"Biogerontology"},{"key":"10.1016\/j.canlet.2004.11.011_bib46","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1053\/meta.2003.50093","article-title":"An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress","volume":"52","author":"Bonnefont-Rousselot","year":"2003","journal-title":"Metabolism"},{"key":"10.1016\/j.canlet.2004.11.011_bib47","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2337\/diabetes.47.4.507","article-title":"PPAR\u03b3: adipogenic regulator and thiazolidinedione receptor","volume":"47","author":"Spiegelman","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.canlet.2004.11.011_bib48","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2337\/diabetes.52.3.667","article-title":"Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy","volume":"52","author":"Phillips","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.canlet.2004.11.011_bib49","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/713608372","article-title":"PPARalpha agonist-induced rodent tumors: modes of action and human relevance","volume":"33","author":"Klaunig","year":"2003","journal-title":"Crit. Rev. Toxicol."},{"key":"10.1016\/j.canlet.2004.11.011_bib50","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/jnci\/92.5.418","article-title":"A ligand of peroxisome proliferators-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions","volume":"92","author":"Mehta","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2004.11.011_bib51","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1470-2045(04)01509-8","article-title":"Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists","volume":"5","author":"Grommes","year":"2004","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2004.11.011_bib52","first-page":"1604","article-title":"Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy","volume":"60","author":"Rubin","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2004.11.011_bib53","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1046\/j.1365-2362.2000.00734.x","article-title":"Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X","volume":"30","author":"Idzior-Walus","year":"2000","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.canlet.2004.11.011_bib54","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/sj.leu.2402843","article-title":"Fibrates and medroxyprogesterone acetate induce apoptosis of primary Burkitt's lymphoma cells and cell lines: potential for applying old drugs to a new disease","volume":"17","author":"Fenton","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2004.11.011_bib55","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/S0140-6736(04)16359-9","article-title":"The nicotinic acid receptor\u2014a new mechanism for an old drug","volume":"363","author":"Karpe","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2004.11.011_bib56","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1207\/S15327914NC4602_02","article-title":"Niacin and carcinogenesis","volume":"46","author":"Kirkland","year":"2003","journal-title":"Nutr. Cancer"},{"key":"10.1016\/j.canlet.2004.11.011_bib57","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/(SICI)1097-0215(19970502)71:3<360::AID-IJC9>3.0.CO;2-W","article-title":"Risk of endometrial cancer in patients with diabetes mellitus","volume":"71","author":"Weiderpass","year":"1997","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2004.11.011_bib58","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2004.11.011_bib59","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2004.11.011_bib60","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11892-004-0014-8","article-title":"Treatment of PCOS with metformin and other insulin-sensitizing agents","volume":"4","author":"Seli","year":"2004","journal-title":"Curr. Diabetes Rep."},{"key":"10.1016\/j.canlet.2004.11.011_bib61","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/09513590312331290298","article-title":"Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent","volume":"17","author":"Session","year":"2003","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.canlet.2004.11.011_bib62","first-page":"175","article-title":"Preliminary evidence on metabolic rehabilitation of cancer patients","volume":"58","author":"Dilman","year":"1988","journal-title":"Arch. f. Geschwulstf."},{"key":"10.1016\/j.canlet.2004.11.011_bib63","unstructured":"L.M. Berstein, T.P. Evtushenko, E.V. Tsyrlina, Yu.F. Bobrov, M.N. Ostroumova, I.G. Kovalenko, V.F. Semiglazov, N.N. Simonov, V.M. Dilman, Comparative study of 5- and 10-years of metabolic rehabilitation of oncological patients, In: Neuroendocrine System, Metabolism, Immunity and Cancer, St. Petersburg, 1992, pp. 102\u2013112."},{"key":"10.1016\/j.canlet.2004.11.011_bib64","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease (4S Study)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2004.11.011_bib65","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.canlet.2004.11.011_bib66","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2004.11.011_bib67","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1161\/01.CIR.0000017634.00171.24","article-title":"Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project","volume":"105","author":"Pfeffer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.canlet.2004.11.011_bib68","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1089\/154099903322447710","article-title":"Lipid-lowering drug use and breast cancer in older women: a prospective study","volume":"12","author":"Cauley","year":"2003","journal-title":"J. Womens Health"},{"key":"10.1016\/j.canlet.2004.11.011_bib69","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0895-4356(02)00614-5","article-title":"Statin use and risk of breast cancer","volume":"56","author":"Beck","year":"2003","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.canlet.2004.11.011_bib70","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1002\/cncr.20271","article-title":"The association between 3-hydroxy-3-methylglutaryl coenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study","volume":"100","author":"Boudreau","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2004.11.011_bib71","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1200\/JCO.2004.02.027","article-title":"The risk of cancer in users of statins","volume":"22","author":"Graaf","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2004.11.011_bib72","series-title":"Proceedings of the 40th ASCO Meeting, New Orleans","article-title":"HMG CoA reductase inhibitors and the risk of colorectal cancer","author":"Poynter","year":"2004"},{"key":"10.1016\/j.canlet.2004.11.011_bib73","article-title":"Statin use and prostate risk","author":"Shannon","year":"2004"},{"key":"10.1016\/j.canlet.2004.11.011_bib74","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1023\/A:1024038127156","article-title":"Use of the peroxisome proliferator-activated receptor (PPAR)\u03b3 ligand troglitazone as treatment for refractory breast cancer: a phase II study","volume":"79","author":"Burstein","year":"2003","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2004.11.011_bib75","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/sj.bjc.6601306","article-title":"A phase II trial with rosiglitazone in liposarcoma patients","volume":"89","author":"Debrock","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2004.11.011_bib76","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00045391-200305000-00007","article-title":"Melanoma chemoprevention: a role for statins or fibrates?","volume":"10","author":"Dellavalle","year":"2003","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.canlet.2004.11.011_bib77","doi-asserted-by":"crossref","first-page":"6831","DOI":"10.1158\/0008-5472.CAN-04-1017","article-title":"Lipid-altering drugs: decreasing cardiovascular disease at the expense of increasing cancer","volume":"64","author":"Goldstein","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2004.11.011_bib78","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jpeds.2003.08.015","article-title":"Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome","volume":"144","author":"Ibanez","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.canlet.2004.11.011_bib79","series-title":"Mothers, Babies and Health in Later Life","author":"Barker","year":"1998"},{"key":"10.1016\/j.canlet.2004.11.011_bib80","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1023\/A:1022570305704","article-title":"Birth weight and risk of early-onset breast cancer","volume":"14","author":"Mellemkjaer","year":"2003","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.canlet.2004.11.011_bib81","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0065-230X(08)60439-X","article-title":"Newborn macrosomy and cancer","volume":"50","author":"Berstein","year":"1988","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.canlet.2004.11.011_bib82","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/01.GME.0000055485.06076.00","article-title":"Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells","volume":"10","author":"Mueck","year":"2003","journal-title":"Menopause"},{"key":"10.1016\/j.canlet.2004.11.011_bib83","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1161\/01.CIR.0000019406.74017.B2","article-title":"Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen\/Progestin Replacement Study (HERS)","volume":"105","author":"Herrington","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.canlet.2004.11.011_bib84","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0305-7372(02)00038-5","article-title":"The metabolic syndrome in long-term cancer survivors, an important target for secondary preventive measures","volume":"28","author":"Nuver","year":"2002","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.canlet.2004.11.011_bib85","doi-asserted-by":"crossref","first-page":"786","DOI":"10.7326\/0003-4819-140-10-200405180-00008","article-title":"Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial","volume":"140","author":"Hadigan","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.canlet.2004.11.011_bib86","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1158\/0008-5472.CAN-03-3645","article-title":"Orlistat is novel inhibitor of fatty acid synthase with antitumor activity","volume":"64","author":"Kridel","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2004.11.011_bib87","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11883-004-0095-5","article-title":"Hypolipidemic therapy and cholesterol absorption","volume":"6","author":"Manhas","year":"2004","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.canlet.2004.11.011_bib88","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(03)14571-0","article-title":"Genetic cause of hyperglycaemia and response to treatment in diabetes","volume":"362","author":"Pearson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2004.11.011_bib89","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1001\/jama.291.23.2821","article-title":"Pharmacogenetic study of statin therapy and cholesterol reduction","volume":"291","author":"Chasman","year":"2004","journal-title":"J. Am. Med. Assoc."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383504008705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383504008705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T01:52:27Z","timestamp":1548899547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383504008705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S0304383504008705"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2004.11.011","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}